1Eckardt KU, ScherhagA, MacdougallIC, et al. Left? ventricular? geometry? predicts cardiovascular outcomes associated with ane- mia correction in CKD. J Am Soc Nephroh 2009,20 (12):2651- 2660.
2Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: An overview. Am J Health Syst Pharm,2007,64(13,Suppl 8) : S.3-S7.
3NKF-K/DOQI . Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease~ 2007 up- date of hemoglobin target. Am J Kidney Dis,2007,50:474.
4Martin Wagner, David Ansell, David M Kent, et al. Predicting mrotality in incident dialysis patients: An analysis of the united kingdom renal registry. Am J Kidney Dis, 2011,57(6) : 894-902.
6Merino A, Nogueras S, Buendia P, et al. Microinflammation and endothelial damage in hemodialysis. Contrib Nephrol, 2008,161: 83-88.
7Gupta A, Zhuo J, Zha J,et al. Effect of different intravenous i- ron preparations on lymphocyte intracellular reactive oxygen spe- cies generation and subpopulation survival. BMC Nephrol,2010, 17:11-16.
9Merle U, Fein E, Gehrke SG, et al. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology, 2007,148 : 2663-2668.
10Feldman H I,Joffe M, Robinson B, et al. Administration of paren- teral iron and mortality among hemodialysis patients. J Am Soc Nephrol, 2004,15 : 1623-1-632.
3Kuragano,T.Kida, A.Furuta,et al.Effects of acetate-free citrate-containing dialysate on metabolic acidosis,anemia,and malnutrition in hemodialysis patients[J].Artificial Organs,2012;26(3):537-539.
4Berenguer N,Ferrindez O,Barbosa F,et aI.Long-term treatment with linezolid in a patient with osteomyelitis undergoing hemodialysis[J].J Chem other,2012;24(4):226-228.
5Santhna L,Srijit D,Hasliza H,et al.Fatigue experienced by patients receiving maintenance dialysis in hemodialysis units[J].Nursing & Health Sciences, 2011;13(1):60-64.
6Kelly RJ,Hill A,Arnold LM,et al.Eculizumab for patients with paroxysmal nocturnal hemoglobinuria (PNH) is effective during the maintenance of hemodialysis for end stage renal failure[J].Leukemia Research,2011 , 25(4):537-539.
